INSULIN RESISTANCE AND HEPATIC MARKERS IN TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL STUDY

Venkata Ramesh  Bonam; P Supriya; Pedda P Reddamma

doi:10.21272/eumj.2024;12(4):886-891

Venkata Ramesh Bonam Department of Biochemistry, Apollo Institute of Medical Sciences and Research Chittoor, Andhra Pradesh, India https://orcid.org/0000-0002-1800-1226
P Supriya Department of Biochemistry, Saveetha Institute of Medical And Technical Sciences Chennai, Tamil Nadu, India; Apollo Institute of Medical Sciences and Research Chittoor, Andhra Pradesh, India https://orcid.org/0009-0001-7133-2526
Pedda P Reddamma Department of Biochemistry, Apollo Institute of Medical Sciences and Research Chittoor, Andhra Pradesh, India https://orcid.org/0009-0005-3458-618X

DOI: https://doi.org/10.21272/eumj.2024;12(4):886-891

Keywords: insulin, C peptide, diabetes mellitus, insulin resistance, liver markers, PON 1

Abstract

Aim: The objective of this study was to compare liver markers and insulin resistance between diabetic and non-diabetic individuals and determine the correlation between diabetic and non-diabetic parameters.

Methods: A cross-sectional study was conducted at the Department of Biochemistry after being approved by the Institutional Ethics Committee. Fasting venous blood was collected for serum analysis of various biochemical parameters, including liver enzymes AST and ALT. Total and direct bilirubin and plasma proteins like total protein, albumin, globulin, A:G ratio were assessed using automated chemistry analyzers. Insulin levels were measured using a hormone analyzer based on electrochemiluminescence. Insulin resistance was calculated using the homeostasis model assessment (HOMA-IR) formula, and PON1 activity was determined using a spectrophotometric method.

Results: The study showed a significant increase in the levels of insulin, liver enzymes, bilirubin, and insulin resistance in T2DM patients compared to controls. Notably, AST and ALT exhibited excellent discriminatory ability as liver markers, with perfect AUC values, while PON1 showed lower AUC values, indicating its limited utility as a liver marker in T2DM. Positive correlations were observed between PON1 and HOMA-IR, as well as between PON1 and insulin levels. These findings suggest that while liver enzymes like AST and ALT are robust markers of liver disease in T2DM, PON1 may not be as effective in predicting liver disease in this population.

Conclusion: The study provides valuable insights into the association between liver markers and insulin resistance in type 2 diabetes mellitus (DM), highlighting the importance of comprehensive liver function assessment in diabetic individuals.

Downloads

Download data is not yet available.

References

Barata Cavalcanti O. et al. Compiled by Tim Lobstein, Hannah Brinsden, and Margot Neveux, with input and review from Acknowledgments. www.worldobesity.org#worldobesityatlas (2022).

De Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22(5):756-61.

Balkau B, Eschwège E, Ducimetière P, Richard JL, Warnet JM. The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J ClinEpidemiol. 1991;44(6):465-74. https://doi.org/10.1016/0895-4356(91)90209-r

Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment PharmacolTher 2005;22(2):24-7.

Olokoba AB, ObateruOA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman medical Journal 2012;27(4):269-273. https://doi.org/10.5001/omj.2012.68

Marchesini G, Bugianesi E, ForlaniG, Cerrelli F, Lenzi M, Manini R et al. Non alcoholic fatty liver, steatohepatitis and the metabolic syndrome. 2003;37:917-923.

Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002;25(5):815-21

Adiga U, Malawadi BN. Alterations in liver enzymes in type 2 diabetes mellitus. Journal of Basic and Applied Medical Sciences2016;3(1):13-16.

Yamada A, Shoji T, Tahara H, Emoto M, Nishizawa Y. Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population. Metabolism. 2001;50(7):805-11. https://doi.org/10.1053/meta.2001.24215

Kedage V, Manjunath S, Shetty M, Suvarna R, Soumya S et al. Serum PON 1 activity status in patients with liver disorders. Saudi J of gastroenterology 2010;16(2):79-83.

Ferre N, Camps J, Prats E, Vilella E, Paul A. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver disease. Clin chem. 2002;48(2):261-8.

Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med. 2005 Aug;22(8):973-9. https://doi.org/10.1111/j.1464-5491.2005.01595.x

Levinthal GN, Tavill AJ. Liver disease and diabetes mellitus. Clin Diabetes 1999; 17:73.

Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844-50.

Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol. 1986; 21(1):109-13. https://doi.org/10.3109/00365528609034632

Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998 Apr; 21(4): 518-24. https://doi.org/10.2337/diacare.21.4.518

Paola PS, Kenneth C. Treatment of NAFLD in patients with type 2 diabetes mellitus. Clinical diabetes & Endocrinology 2016;2:9.

Rehman A, Zamir S, Bhatti A, Jan SS, Ali S, Wazir F. Evaluation of albuminuria, total plasma proteins and serum albumin in diabetics. Gomal J Med Sci 2012; 10: 198-200.

Al Ghamdi K. Micro albuminuria among patients with diabetes type 1 and type 2 at the Armed Forces Hospital in Jubail. Annals Saudi Med 2001; 21: 236-8. https://doi.org/10.5144/0256-4947.2001.236

Kawai T, Clinical Aspects of the Plasma Proteins. J. B. Lippincott, Philadelphia, 1973, section IV.

Sun T, Lien Y Y, Gross S. Clinical application of a high-resolution electrophoresis system, Ann Clin Lab Sci 1978;8: 219.

Ritchie R F. Automated nephelometric analysis apecific serum proteins: clinical applications, in Protides of the Biological Fluids (21st colloquium 1973), Peeters, H., Ed., Pergamon Press, Oxford, 1974, 593.

Laurell CB. Is Eletrophoretic analysis of plasma proteins becoming out-dated? Scand J Clin Lab Invest 1972; 30:233. https://doi.org/10.3109/00365517209084284

Coppola G, Corrado E, Tantillo R, Vitale G, Lo Coco L, Novo S. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol. 2006; 106(1): 16-20. https://doi.org/10.1016/j.ijcard.2004.12.051

Ardavi MS, Nasrat HA, Bahnassy AA. Serum Immunoglobulin concentrations in diabetic patients. Diabetic Med 1994; 11: 384-87.

Liu J, Dong H, Zhang Y, Cao M, Song L, Pan Q, Bulmer A, Adams DB, Dong X, Wang H. Bilirubin Increases Insulin Sensitivity by Regulating Cholesterol Metabolism, Adipokines and PPARγ Levels. Sci Rep. 2015;28(5):9886. doi: 10.1038/srep09886. Erratum in: Sci Rep. 2016 Jan 20;6:19170. https://doi.org/10.1038/srep19170.

Dong H et al. Bilirubin Increases Insulin Sensitivity in Leptin-Receptor Deficient and Diet-Induced Obese Mice Through Suppression of ER Stress and Chronic Inflammation. Endocrinology 2014; en20131667.

Sunil K K, Lalit K. Meher, Siva K, Sruti J, Krishna SVS, Kirtikumar DM. Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian Journal of Endocrinology and Metabolism 2013; 17 (3):402-412.

Suvarna R, Rao S, Joshi C, Kedage V, Muttigi MS, Shetty JK , Mungli P. Paraoxonase Activity In Type 2 Diabetes Mellitus Patients With And Without Complications. Journal of Clinical and Diagnostic Research. 2011; 5(1):63-65.

Tabur S, Torun AN, Sabuncu T, Turan MN, Celik H, Ocak AR, et al. Nondiabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect stress and inflammation. Eur J Endocrinol 2010;162: 535-41. https://doi.org/10.1530/eje-09-0732

Beer S, Moren X, Ruiz J, James RW. Postprandial modulation of serum paraoxonase activity and concentration in diabetic and non-diabetic subjects. NutrMetab Cardiovasc Dis 2006; 16:457-65.

Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J. Lack of association between paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab. 2003;88:1711-6.

Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: A comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 2004; 89: 2957-62.

Karabina SA, Lehner AN, Franke E, Parthasara S, Santanam N. Oxidative inactivation of paraoxonase—implications in diabetes mellitus and atherosclerosis. BiochimBiophys Acta 2005;1725:21321.

Flekac M, Skrha J, Zidkova K, Lacinova Z, Hilgertova J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res 2008;57:717-26.